清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial

医学 阿托伐他汀 养生 临床终点 血脂异常 人口 复视 内科学 外科 随机对照试验 Graves眼病 格雷夫斯病 疾病 环境卫生
作者
Giulia Lanzolla,Elena Sabini,Marenza Leo,Francesca Menconi,Roberto Rocchi,Angela Tindara Sframeli,Paolo Piaggi,Marco Nardi,Claudio Marcocci,Michele Marinò
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:9 (11): 733-742 被引量:54
标识
DOI:10.1016/s2213-8587(21)00238-2
摘要

Background A protective action of statins on development of Graves' orbitopathy suggests that statins might be used for treatment of the disease. We aimed to assess the efficacy of the addition of a statin, atorvastatin, to intravenous glucocorticoids (ivGCs) on Graves' orbitopathy outcomes in patients with hypercholesterolaemia. Methods We did a randomised, open-label, phase 2, adaptive, clinical trial at a single, tertiary, referral hospital in Pisa, Italy. Patients with moderate-to-severe, active Graves' orbitopathy, with a low-density lipoprotein cholesterol concentration between 2·97 and 4·88 mmol/L were eligible for inclusion. Patients were randomly assigned (1:1) in 11 blocks of eight, using a computer-based system, to the ST group or the NST group. The ST group received ivGCs (methylprednisolone 500 mg once a week for 6 weeks followed by 250 mg once a week for an additional six weeks) for 12 weeks and oral atorvastatin (20 mg once a day) for 24 weeks. The NST group only received the ivGC regimen. Patients were unmasked to group allocation; however, the ophthalmological investigator was masked to randomisation. The primary endpoint was the Graves' orbitopathy outcome (composite evaluation of exophthalmos, clinical activity score, eyelid aperture, and diplopia) at 24 weeks in the modified intention-to-treat (ITT) population (patients who attended the week 12 visit). Patients were considered responders when at least two of the following criteria were fulfilled in the most affected eye, without worsening in any of the same measures in both eyes: (1) reduction in exophthalmos of 2 mm or more, with no increase by 2 mm or more in the other eye; (2) reduction of clinical activity score by two or more points; (3) reduction in eyelid aperture by 2 mm or more, with no increase by 2 mm or more in the other eye; and (4) disappearance or improvement (change from constant to inconstant, intermittent, or absent, or from inconstant to intermittent or absent) of diplopia, and (5) improvement in visual acuity by 0·2 decimals or more. The trial is registered with EUDRACT, 2018-001317-33, and ClinicalTrials.gov, NCT03110848. Findings Between June 1, 2020, and Nov 30, 2020, 119 patients were screened for inclusion, of whom 88 (74%) patients were enrolled and randomly assigned to one of the two treatment groups (44 [50%] to the ST group and 44 [50%] to the NST group). Eight (9%) patients did not attend the 12 week visit; 80 (91%) patients (18 [23%] men and 62 [78%] women) were included in the modified ITT population (41 [51%] in the ST group and 39 [49%] in the NST group]. The proportion of Graves' orbitopathy composite evaluation responders at 24 weeks was higher in the ST group (21 [51%] of 41 patients) than the NST group (11 [28%] of 39 patients; attributable risk 0·23 [95% CI 0·02–0·44]; p=0·042). 26 adverse events occurred in 21 (24%) of 88 patients in the safety population. One (2%) of 44 patients in each group required treatment discontinuation, with no serious adverse events and no difference between groups. Interpretation Addition of oral atorvastatin to an ivGC regimen improved Graves' orbitopathy outcomes in patients with moderate-to-severe, active eye disease who were hypercholesterolaemic. Future phase 3 studies, which could potentially recruit patients regardless of low-density lipoprotein cholesterol concentration, are required to confirm this association. Funding Associazione Allievi Endocrinologia Pisana.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xdd完成签到 ,获得积分10
5秒前
风华完成签到,获得积分10
12秒前
25秒前
herpes完成签到 ,获得积分10
29秒前
GGBond完成签到 ,获得积分10
47秒前
livinglast完成签到 ,获得积分10
56秒前
59秒前
Rondab应助雪山飞龙采纳,获得10
1分钟前
梵莫完成签到,获得积分10
1分钟前
sherry完成签到 ,获得积分10
1分钟前
Young完成签到 ,获得积分10
1分钟前
xue完成签到 ,获得积分10
1分钟前
丘比特应助科研通管家采纳,获得10
1分钟前
林利芳完成签到 ,获得积分0
2分钟前
研友_8y2G0L完成签到,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
小焦儿发布了新的文献求助10
2分钟前
2分钟前
吃的饭广泛应助小焦儿采纳,获得10
2分钟前
谭平完成签到 ,获得积分10
2分钟前
科研的豪哥完成签到 ,获得积分10
3分钟前
小焦儿完成签到,获得积分10
3分钟前
完美梨愁完成签到 ,获得积分10
3分钟前
wanci应助无限的以亦采纳,获得10
3分钟前
糟糕的翅膀完成签到,获得积分10
3分钟前
creep2020完成签到,获得积分10
3分钟前
谭凯文完成签到 ,获得积分10
3分钟前
lorentzh完成签到,获得积分10
3分钟前
3分钟前
YX完成签到 ,获得积分10
3分钟前
4分钟前
Sandy应助Am采纳,获得20
4分钟前
桐桐应助嘿嘿嘿侦探社采纳,获得10
4分钟前
ycool完成签到 ,获得积分10
4分钟前
小强完成签到 ,获得积分10
4分钟前
大树完成签到 ,获得积分10
4分钟前
4分钟前
4分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968521
求助须知:如何正确求助?哪些是违规求助? 3513341
关于积分的说明 11167298
捐赠科研通 3248700
什么是DOI,文献DOI怎么找? 1794434
邀请新用户注册赠送积分活动 875030
科研通“疑难数据库(出版商)”最低求助积分说明 804664